Skip to main content
Frontiers in Genetics logoLink to Frontiers in Genetics
. 2026 Nov 2;17:1969094. doi: 10.3389/fgene.2026.1969094

Longitudinal characterization of a Leigh-like presentation associated with the MT-ND4 m.11470A>C variant

Liang Li 1,†, Hao Ling 1,2,†, Kun Cheng 1, Ya-qian Zhang 1, Hong Liu 1,2,*
PMCID: PMC13770849  PMID: 43041252

Abstract

Leigh syndrome comprises genetically heterogeneous mitochondrial disorders, but interpretation of rare mitochondrial DNA variants is often limited by sparse longitudinal data. We report a male patient followed from childhood to age 16 with the MT-ND4 m.11470A>C (p. (Lys237Asn)) variant. Right-eye strabismus and optic atrophy appeared at age 3, followed by progressive limb weakness, gait instability, and dysarthria. At age 16, magnetic resonance imaging showed bilateral lesions involving the basal ganglia, thalami, midbrain, pons, and medulla oblongata. The patient subsequently developed respiratory failure requiring intubation and mechanical ventilation. The variant was detected in saliva at a pipeline-reported heteroplasmy level of 51.8% and was not detected by Sanger sequencing in saliva from the mother or dizygotic twin brother. APOGEE 2 predicted a potential deleterious effect, the affected residue was conserved, and static structural visualization suggested altered local contacts. A targeted review identified previous associations of m.11470A>C with MELAS and a Leigh syndrome record in a pediatric cohort. This detailed longitudinal case adds clinical and neuroimaging resolution to the reported m.11470A>C spectrum and supports integrating disease trajectory, tissue source, heteroplasmy, and family data when interpreting rare mitochondrial DNA variants.

Keywords: heteroplasmy, Leigh syndrome, m.11470A>C, mitochondrial DNA, MT-ND4, phenotype

1. Introduction

Leigh syndrome is a progressive mitochondrial encephalopathy characterized by neurological deterioration and bilateral lesions of the basal ganglia, brainstem, or both. Its genetic basis spans mitochondrial and nuclear genomes, and the relationship between a specific variant and clinical presentation is often modified by heteroplasmy, tissue distribution, and genetic background (Toutain et al., 2025; McCormick et al., 2023; Lim et al., 2022).

MT-ND4 encodes a membrane subunit of mitochondrial respiratory complex I. Variants in MT-ND4 have been associated with Leigh syndrome, Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS), optic neuropathy, and other mitochondrial phenotypes (McCormick et al., 2023; Zhao et al., 2011). The m.11470A > C substitution, which changes lysine 237 to asparagine, was reported in a Chinese MELAS cohort (Zhao et al., 2011). A later pediatric cohort also recorded the variant in one patient classified as having Leigh syndrome, but did not provide an individual longitudinal description (Zhu et al., 2021).

Here, we provide a 13-year clinical, neuroimaging, and genetic characterization of a patient with a Leigh-like presentation associated with m.11470A>C. We also place the case within a targeted review of reported MT-ND4 phenotypes and reassess the strength of the variant evidence using mitochondrial DNA-specific interpretation criteria.

2. Materials and methods

2.1. Patient evaluation and ethics

A 16-year-old male was admitted with a 13-year history of right-eye strabismus, a 3-year history of limb weakness, and dyspnea for 1 week. After obtaining written informed consent from the patient and his legal guardian, we collected the patient’s clinical data, including physical examination, laboratory tests, and cranial MRI findings. This written informed consent form includes the publication of case text, test results, imaging data, sequencing images, and genetic/family information.

2.2. Genetic analysis

Saliva samples were obtained from the proband, his mother, and his dizygotic twin brother. Genomic DNA was extracted with the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany). DNA concentration and purity were assessed with a Qubit 4.0 fluorometer and NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, United States).

Whole exome sequencing (WES) was performed by a clinical laboratory. We received the final clinical sequencing report and did not have access to raw sequencing data. Whole-exome sequencing was performed with the Illumina DNA Prep with Exome 2.5 Enrichment kit on a NovaSeq 6000 platform (Illumina, San Diego, CA, United States) using 150-bp paired-end reads. The clinical WES target comprised 20,858 nuclear genes, including nuclear genes associated with Leigh syndrome and mitochondrial encephalopathies (Specific gene list can be found in Supplementary Table S1). Mitochondrial reads were recovered from off-target WES data and processed with an in-house mitochondrial genome pipeline. The mitochondrial genome analysis included 37 mitochondrial genes. Candidate variants were evaluated by Sanger sequencing in the proband and tested relatives.

2.3. In silico and structural analyses

The missense variant was assessed with APOGEE 2, a mitochondria-specific ensemble predictor with scores ranging from 0 to 1. ND4 sequences from 12 species were aligned with ClustalW and visualized in Jalview to assess residue conservation.

Static structural visualization was performed in PyMOL version 2.5 (Schrödinger, New York, NY, United States) using the cryo-electron microscopy structure of human mitochondrial complex I (PDB 6ZR2). The Lys237Asn substitution was introduced with the mutagenesis tool, and local residue contacts were inspected by distance measurement. This analysis was treated as hypothesis-generating and not as functional validation.

2.4. Variant interpretation

Evidence was reassessed with the mitochondrial DNA-specific ACMG/AMP specifications proposed by McCormick et al. (2020). Evidence codes were applied only when the available data met the mitochondrial DNA-specific definitions. A negative Sanger result in a single maternal tissue was not considered sufficient to confirm a de novo event or to apply the PS2 criterion; therefore, the family findings were described as apparently de novo.

2.5. Targeted literature review

PubMed was searched on October 14, 2026 using the terms (MT-ND4 OR ND4 OR “NADH dehydrogenase subunit 4”) AND (Leigh OR MELAS OR encephalopathy OR optic neuropathy). The search returned 359 records. After removal of duplicates 359 records were screened by title and abstract. Titles and abstracts were screened by two authors (L.L. and H.L.), and disagreements were resolved by consensus. 150 full-text articles were assessed for eligibility. Studies were included if they reported human case reports or case series with an MT-ND4 point variant or a mitochondrial deletion involving MT-ND4 together with clinical phenotype data. Experimental studies without human phenotype data were excluded. Point variants and large deletions were summarized separately because a multigene deletion cannot support an MT-ND4-specific inference. A total of eight point variants from 16 articles and 2 large deletions from 2 articles were included.

3. Results

3.1. Longitudinal clinical course and neuroimaging (Supplementary Table S2)

This male patient had right-eye strabismus and optic atrophy documented at age 3. MRI performed at age 3 was reported to show bilateral basal ganglia signal abnormalities. However, due to the passage of time, the original imaging data was no longer available. Over the following decade, the patient developed left upper-limb weakness, gait instability, and dysarthria. At age 16, he was admitted with inspiratory dyspnea.

Neurological examination at age 16 showed dysarthria, restricted movement of the right eye, left eye exotropia, decreased visual acuity, ptosis, grade 4 muscle strength in all four limbs, and clumsy finger-to-nose and rapid alternating movements. Serum lactate was 1.52 mmol/L. MRI showed bilateral signal abnormalities in the basal ganglia, thalami, midbrain, pons, and medulla oblongata (Figure 1). The progressive neurological course and bilateral basal ganglia and brainstem lesions were considered consistent with a Leigh syndrome.

FIGURE 1.

Series of brain MRI scan slices in three rows labeled A, B, and C, each with 6 images displaying transverse sections. White arrows point to lesions in bilateral basal ganglia, thalami, midbrain, pons, and medulla oblongata in each sequence.

Cranial MRI at age 16. Axial images show bilateral signal abnormalities in the basal ganglia, thalami, midbrain, pons, and medulla oblongata (arrows). Rows show (A) T1-weighted, (B) T2-weighted, and (C) FLAIR sequences.

During hospitalization, respiratory failure required intubation and mechanical ventilation, which was initiated in SIMV + PSV mode with FiO2 40%, PEEP 5 cmH2O, and VT 8 mL/kg. Consciousness declined to stupor; the pupils were 2.0 mm bilaterally and remained reactive to light. In addition to supportive care, a mitochondrial cocktail was administered (Coenzyme Q10 300 mg/d, divided into three oral doses; levocarnitine 2 g/d, intravenous drip; idebenone 90 mg/d; Vitamin B1 300 mg/d; Vitamin B2 50 mg/d; and Vitamin B6 30 mg/d). Due to the patient’s articulation disorders and swallowing difficulties, a nasogastric tube was placed for enteral nutrition support.

Invasive mechanical ventilation lasted for 11 days. On the 8th day after admission, the patient’s consciousness changed from stupor to drowsiness, and the pupils recovered to 2.5 mm and reactive to light. His spontaneous breathing rhythm tended to be regular. Re-examination of arterial blood gas (at FiO2 30%) showed PaO2 88 mmHg, PaCO2 42 mmHg, and pH 7.40. On the 12th day, the endotracheal tube was successfully removed, followed by nasal high flow humidified oxygen therapy (FiO2 28%, flow rate 35 L/min), and then gradually transitioned to nasal cannula oxygen therapy (2 L/min), with blood oxygen saturation maintained at 95%–98%.

The patient’s clinical status gradually improved during hospitalization. However, because invasive mechanical ventilation, oxygen therapy, enteral nutrition, and the mitochondrial cocktail were administered concurrently, and because no objective efficacy endpoints were available, the contribution of the mitochondrial cocktail to this improvement cannot be determined. At the time of discharge, the patient’s consciousness was clear, the questions and answers were relevant, and the articulation disorder was reduced compared to before. The limb muscle strength improved to grade 4+/5. With the help of others, the patient was able to walk short distances. The finger nose test and rapid rotation movements improved compared to when admitted, but there was still mild ataxia in the left limb and blurred vision. Before discharge, a follow-up head MRI showed no significant progression of abnormal signals in the brainstem and basal ganglia, and blood lactate decreased to 0.98 mmol/L.

After discharge, the patient continued to receive coenzyme Q10, idebenone, and B vitamins, and was regularly followed up at the neurology clinic. At the three-month telephone and outpatient follow-up, the patient was able to walk independently at home (with slightly unstable gait), without the need for assisted ventilation. Oral feeding was good (nasogastric tube has been removed), and no respiratory failure or consciousness disorders have occurred again. Daily life self-care (Barthel index score 65), articulation disorders and limb weakness symptoms did not progressively worsen compared to discharge.

Collectively, according to the diagnostic criteria of Leigh syndrome spectrum (McCormick et al., 2023), the progressive neural processes and bilateral basal ganglia and brainstem lesions were consistent with the neuroimaging core criterion of the Leigh syndrome spectrum. However, the absence of biochemical or mitochondrial abnormality meant that the full diagnostic criteria for Leigh syndrome were not met. Confirmatory neuropathology was also not available. Consequently, the presentation of this patient was termed Leigh-like presentation.

3.2. Genetic findings and family testing

The clinical WES target comprised 20,858 nuclear genes and spanned 37,837,472 bp. Target coverage was 99.72%, mean depth was 127.27×, and 97.97% of target bases were covered at ≥20×. The nuclear genes associated with Leigh syndrome and mitochondrial encephalopathies were included in this WES target set. No pathogenic or likely pathogenic nuclear variant concordant with the patient’s phenotype was identified within the laboratory’s established analytical scope and reporting thresholds. The clinical report listed two heterozygous variants in autosomal recessive genes as suspected pathogenic findings: DNAJB2 c.91C>T, p. His31Tyr, and GUSB c.1145G>A, p. Arg382His. Each variant was heterozygous in an autosomal recessive condition, neither was phenotype-concordant, and neither was validated in parents. They were therefore not considered explanatory.

Mitochondrial reads were recovered from off-target WES data and processed with an in-house mitochondrial genome pipeline. The mitochondrial genome analysis included 37 mitochondrial genes and spanned 16,569 bp. The mitochondrial reference genome was covered at 100%, with a mean depth of 15,848.91×, and 100% of sites were covered at ≥20×. The m.11470A>C variant, which remains classified as a VUS, was identified in the proband’s saliva. The heteroplasmy level was 51.8%, derived directly from the NGS read fraction, that is, the mutant allele frequency calculated from total reads covering the locus, rather than from Sanger chromatogram peak-height quantitation. The laboratory’s stated detection limit for heteroplasmic variants by this platform is approximately 25%, and the reported level of 51.8% exceeds this general threshold. However, site-specific read counts, including total depth, reference and mutant read numbers, strand bias, and NUMT filtering, were not available in the provided sequencing report. Therefore, the 51.8% value is treated as a pipeline-reported heteroplasmy level rather than an independently confirmed quantitative measure. No other mitochondrial DNA variant exceeding the laboratory’s reporting threshold was detected in the proband’s mitochondrial genome reads.

Sanger sequencing confirmed the heteroplasmic state in the proband, whereas the variant was not detected in saliva from the mother or dizygotic twin brother (Figure 2). However, the mother was only tested by PCR-Sanger sequencing, with no NGS data available, and the Sanger detection limit for heteroplasmic variants is reported as ∼25% by the testing laboratory. Furthermore, maternal biological relationship was not confirmed by polymorphic marker analysis. Therefore, although the family findings are compatible with an apparently de novo event, low-level (particularly <25%) or tissue-restricted maternal heteroplasmy cannot be definitively excluded. The whole-exome sequencing data were also systematically interrogated for pathogenic variants in nuclear genes implicated in Leigh syndrome and other mitochondrial encephalopathies. No pathogenic or likely pathogenic nuclear gene variants were identified within the laboratory’s established analytical scope and standard reporting thresholds. Furthermore, no other mitochondrial DNA variants exceeding the laboratory’s reporting threshold were detected in the proband’s mitochondrial genome reads.

FIGURE 2.

Three DNA sequencing chromatograms labeled A, B, and C are aligned vertically, each showing colored peaks representing nucleotide bases with corresponding letter codes above. Red arrows indicate specific positions in each sequence, emphasizing analyzed or mutated regions.

Sanger sequencing chromatograms at mitochondrial DNA position m.11470. (A) The proband shows overlapping (A,C) signals (arrow). Only the reference signal was detected in saliva from (B) the dizygotic twin brother and (C) the mother. Sanger sequencing was used for orthogonal confirmation and not for quantitative heteroplasmy measurement.

Consequently, the PS2 criterion (de novo, confirmed in parents) was not applied in the ACMG classification because a confirmed de novo event was not established. The variant therefore remains classified as a variant of uncertain significance (VUS), supported by PM2_Supporting (absent from population databases) and PP3_Supporting (APOGEE 2, a mitochondria-specific ensemble predictor, returned a deleterious score of 0.9). This classification is consistent with the original clinical laboratory report, which also classified the variant as VUS based on the same evidence codes.

3.3. Computational evidence and conservative variant classification

APOGEE 2 returned a score of 0.9, and Lys237 was conserved across the 12 aligned species (Figure 3). Static visualization placed residue 237 within a transmembrane helix and suggested altered local contacts after substitution of lysine by asparagine (Figure 4). The model did not directly test proton translocation, complex I assembly, or respiratory-chain function.

FIGURE 3.

A multiple sequence alignment of a protein region from twelve species is shown, with amino acids color-coded by type. A red box and arrow highlight lysine at position 237. Below, bar graphs display conservation, alignment quality, consensus sequence, and occupancy data, with higher values indicated by taller bars. Species names are listed on the left, text labels annotate key features, and alignment gaps are marked with dashes.

Multiple-sequence alignment of ND4 across 12 species. The boxed position indicates lysine 237. Conservation, alignment quality, consensus sequence, and occupancy are shown below the alignment.

FIGURE 4.

Protein ribbon diagram in green shows the location of residue 237, with enlarged views comparing wild-type (WT) and mutant (Mut) structures. Insets display atomic interactions and labeled residues at position 237, highlighting changes in side-chain interactions and distances in the mutant compared to wild-type.

Static structural visualization of the p. (Lys237Asn) substitution in human mitochondrial complex I (PDB 6ZR2). The overview locates residue 237, and the enlarged wild-type (WT) and substituted (Mut) views show model-derived local distances, with dashed lines indicating spatial distances (in Å) measured between adjacent residues using PyMOL’s distance tool. The visualization suggests altered local contacts but does not establish a functional effect.

Reassessment under mitochondrial DNA-specific ACMG/AMP criteria, applying only evidence codes that met the mitochondrial DNA-specific definitions, did not alter the original VUS classification. PM1 was not applied because the mitochondrial DNA specifications do not use this criterion; PP3 was retained only at supporting strength; and PP4 was not applied because the required biochemical evidence was unavailable. A de novo code was not applied because maternal testing was limited to saliva and Sanger sequencing. The variant was therefore treated conservatively as a variant of uncertain significance, while the repeated disease associations and the present phenotype were considered clinically informative.

3.4. Literature context

The targeted review showed that individually reported MT-ND4 point variants span Leigh syndrome, MELAS, atypical MELAS, optic-neuropathy-plus, and late-onset encephalopathy phenotypes (Supplementary Tables S3A,B). Large mitochondrial deletions involving MT-ND4 were analyzed separately and were not used to infer an MT-ND4-specific phenotype.

For m.11470A>C specifically, Zhao et al. reported the variant in a Chinese cohort ascertained for MELAS and MELAS/Leigh overlap (Zhao et al., 2011). A case report from 2021 showed a patient classified as Leigh syndrome who also had the m.11470A > C mutation, but did not provide personal longitudinal details (Zhu et al., 2021). Accordingly, the contribution of the present case is a detailed longitudinal characterization rather than a claim of the first Leigh syndrome association.

4. Discussion

This report adds a 13-year clinical history, including detailed characterization of the acute presentation at age 16 and short-term follow-up, to the reported phenotypic spectrum of MT-ND4 m.11470A > C. The patient progressed from childhood ocular abnormalities and optic atrophy to limb weakness, gait instability, dysarthria, extensive bilateral basal ganglia and brainstem lesions, and respiratory failure requiring invasive ventilation. The clinical trajectory, neuroimaging, and genetic findings support a potential association with the Leigh phenotype, while the data do not independently establish molecular causality.

The main alternative phenotype to consider is MELAS, given that m.11470A>C was initially reported in a Chinese MELAS/MELAS–Leigh overlap cohort in a 36-year-old woman with stroke-like episodes and cortical lesions (Zhao et al., 2011). A later pediatric cohort reported m.11470A > C in one patient classified as having Leigh syndrome (Zhu et al., 2021). These findings suggest that m.11470A > C may be associated with more than one mitochondrial phenotype. MELAS is classically defined by mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; clinically, it may manifest with stroke-like attacks, seizures, headache, and vomiting, and imaging typically shows cortical lesions, often asymmetric or migratory (Fan et al., 2021; Będkowska et al.,2022). In contrast, our patient presented in childhood with strabismus, optic atrophy, symmetric basal ganglia and brainstem lesions, and no stroke-like episodes. This pattern is more consistent with the Leigh syndrome spectrum than with classic MELAS. However, MT-ND4 variants can produce overlapping and age-dependent phenotypes, and transitions between Leigh syndrome and MELAS have been reported for other MT-ND variants (Kori et al., 2019). Given that m.11470A>C has been reported in both MELAS and Leigh syndrome phenotypes, and that the present patient shows a Leigh-like presentation, we describe the phenotype at the presentation level rather than assigning the variant to a single diagnostic category.

Phenotypic variation is expected in mitochondrial disease because heteroplasmy and threshold effects differ across tissues and over time (Ahmadi and Brandt, 2025; Johnston, 2019; Grady et al., 2018; Macken et al., 2021). However, the 51.8% value in this patient was measured only in saliva at one time point. During follow-up, we considered additional non-invasive sampling, including urinary epithelial cells and buccal swabs, to assess tissue-related heteroplasmy variation. However, owing to financial constraints, the patient and his family declined further testing. Therefore, the tissue distribution of m.11470A > C remains uncharacterized, and the saliva-based heteroplasmy value should not be extrapolated to clinically affected tissues such as brain and muscle, nor can it explain the absence of symptoms in relatives in whom the variant was not detected. The family results therefore contribute descriptive context rather than direct evidence for a tissue threshold.

The computational findings provide supporting, hypothesis-generating evidence. APOGEE 2 and residue conservation indicate that the substitution is not readily dismissed as neutral, while the static model suggests a local structural change. The predicted transmembrane location of Lys237 adds a further structural consideration. This residue is a conserved charged component of the proton-translocation pathway within the ND4 subunit, where it participates in a network of ion pairs and water-mediated proton transfer (Agip et al., 2018; Röpke et al., 2020). Its protonation state regulates local conformational changes that propagate to the ND4–ND5 interface (Röpke et al., 2020). Substitution of this positively charged lysine with a neutral, polar asparagine is therefore expected to be energetically unfavorable within the hydrophobic environment of transmembrane helix 8, potentially disrupting the local helical geometry and the ion-pair network required for proton translocation. Furthermore, loss of the positive charge at this position may impair the conformational coupling between ND4 and ND5, affecting the stability or assembly of the distal membrane arm of complex I (Sánchez-Caballero et al., 2016). However, no functional evidence currently demonstrates that m.11470A > C impairs complex I activity, assembly, or proton translocation. The absence of muscle biochemical testing, multi-tissue heteroplasmy measurements, and functional assays limits the certainty of pathogenic classification, but it does not remove the clinical value of documenting the associated phenotype.

This case does not justify changing gene-panel composition because MT-ND4 is already an established mitochondrial disease gene. Its practical contribution is more specific: m.11470A>C should be interpreted across mitochondrial syndrome boundaries, with attention to disease trajectory, neuroimaging, tissue source, heteroplasmy, and family data. Further individually documented cases and functional studies will be needed to determine the variant’s molecular effect and penetrance.

5. Conclusion

This longitudinal case broadens the clinical characterization of the MT-ND4 m.11470A > C spectrum by describing a progressive Leigh-like presentation in a patient harboring the variant with extensive basal ganglia and brainstem involvement. The findings support a phenotype-level association and illustrate the need for evidence-calibrated interpretation of rare mitochondrial DNA variants. However, the variant remains a VUS and causality is not established.

Acknowledgments

The authors thank the patient and his family for their cooperation. During the preparation of this work, the authors used OpenAI ChatGPT (GPT-5.6 Sol; OpenAI, San Francisco, California, United States) for language polishing. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the final manuscript.

Funding Statement

The author(s) declared that financial support was not received for this work and/or its publication.

Footnotes

Edited by: Nafisa M. Jadavji, Southern Illinois University Carbondale, United States

Reviewed by: Annamaria Sapuppo, Università degli Studi di Catania, Italy

Raul Fernando Vega Alvear, Hospital Regional de la Orinoquia ESE, Colombia

Data availability statement

The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the de-identified final clinical sequencing report supporting the conclusions of this article should be directed to the corresponding author/s, subject to institutional ethical approval.

Ethics statement

The requirement of ethical approval was waived by Ethics Committee of Heping Hospital Affiliated to Changzhi Medical College for the studies involving humans because For anonymous observational single case reports that do not involve trials, for adults, after obtaining written informed consent from the patient, patient related information can be anonymized for manuscript publication without ethical approval. For minors, after obtaining written informed consent from the patients’ legal guardian, patient related information can be anonymized and used for manuscript publication without ethical approval. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)' legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

LL: Writing – original draft, Writing – review and editing. HaL: Writing – original draft, Writing – review and editing. KC: Writing – review and editing, Investigation. Y-qZ: Writing – review and editing. HoL: Conceptualization, Project administration, Supervision, Writing – review and editing.

Conflict of interest

The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declared that generative AI was used in the creation of this manuscript. During the preparation of this work, the authors used OpenAI ChatGPT (GPT-5.6 Sol; OpenAI, San Francisco, California, United States) for language polishing. After using this tool, the authors reviewed and edited the content as needed and take full responsibility for the final manuscript.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2026.1969094/full#supplementary-material

Table1.docx (73.4KB, docx)

References

  1. Agip A. A., Blaza J. N., Bridges H. R., Viscomi C., Rawson S., Muench S. P., et al. (2018). Cryo-EM structures of complex I from mouse heart mitochondria in two biochemically defined states. Nat. Struct. Mol. Biol. 25 (7), 548–556. 10.1038/s41594-018-0073-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Ahmadi Z. A., Brandt U. (2025). The genotype/phenotype conundrum of inherited mitochondrial disorders: insights from a survey of mtDNA mutations associated with leigh syndrome in complex I. Biochim. Biophys. Acta Mol. Basis Dis. 1871, 167996. 10.1016/j.bbadis.2025.167996 [DOI] [PubMed] [Google Scholar]
  3. Będkowska N., Zontek A., Paprocka J. (2022). Stroke-like episodes in inherited neurometabolic disorders. Metabolites 12 (10), 929. 10.3390/metabo12100929 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Fan H. C., Lee H. F., Yue C. T., Chi C. S. (2021). Clinical characteristics of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. Life (Basel) 11 (11), 1111. 10.3390/life11111111 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Grady J. P., Pickett S. J., Ng Y. S., Alston C. L., Blakely E. L., Hardy S. A., et al. (2018). mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease. EMBO Mol. Med. 10, e8262. 10.15252/emmm.201708262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Johnston I. G. (2019). Varied mechanisms and models for the varying mitochondrial bottleneck. Front. Cell. Dev. Biol. 7, 294. 10.3389/fcell.2019.00294 [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kori A., Hori I., Tanaka T., Aoyama K., Ito K., Hattori A., et al. (2019). Transition from Leigh syndrome to MELAS syndrome in a patient with heteroplasmic MT-ND3 m.10158T>C. Brain Dev. 41 (9), 803–807. 10.1016/j.braindev.2019.05.006 [DOI] [PubMed] [Google Scholar]
  8. Lim A. Z., Ng Y. S., Blain A., Jiminez-Moreno C., Alston C. L., Nesbitt V., et al. (2022). Natural history of Leigh syndrome: a study of disease burden and progression. Ann. Neurol. 91, 117–130. 10.1002/ana.26260 [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Macken W. L., Vandrovcova J., Hanna M. G., Pitceathly R. D. S. (2021). Applying genomic and transcriptomic advances to mitochondrial medicine. Nat. Rev. Neurol. 17, 215–230. 10.1038/s41582-021-00455-2 [DOI] [PubMed] [Google Scholar]
  10. McCormick E. M., Lott M. T., Dulik M. C., Shen L., Attimonelli M., Vitale O., et al. (2020). Specifications of the ACMG/AMP standards and guidelines for mitochondrial DNA variant interpretation. Hum. Mutat. 41, 2028–2057. 10.1002/humu.24107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. McCormick E. M., Keller K., Taylor J. P., Coffey A. J., Shen L., Krotoski D., et al. (2023). Expert panel curation of 113 primary mitochondrial disease genes for the leigh syndrome spectrum. Ann. Neurol. 94, 696–712. 10.1002/ana.26716 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Röpke M., Saura P., Riepl D., Pöverlein M. C., Kaila V. R. I. (2020). Functional water wires catalyze long-range proton pumping in the mammalian respiratory complex I. J. Am. Chem. Soc. 142 (52), 21758–21766. 10.1021/jacs.0c09209 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Sánchez-Caballero L., Guerrero-Castillo S., Nijtmans L. (2016). Unraveling the complexity of mitochondrial complex I assembly: a dynamic process. Biochim. Biophys. Acta 1857 (7), 980–990. 10.1016/j.bbabio.2016.03.031 [DOI] [PubMed] [Google Scholar]
  14. Toutain G., Hoebeke C., Gastaldi M., Milh M., Chabrol B. (2025). Mitochondrial Leigh syndrome: the state of the art. Arch. Pediatr. 32, 509–516. 10.1016/j.arcped.2025.04.007 [DOI] [PubMed] [Google Scholar]
  15. Zhao D., Hong D., Zhang W., Yao S., Qi X., Lv H., et al. (2011). Mutations in mitochondrially encoded complex I enzyme as the second common cause in a cohort of Chinese patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes. J. Hum. Genet. 56, 759–764. 10.1038/jhg.2011.96 [DOI] [PubMed] [Google Scholar]
  16. Zhu H., Chen W., Chen L., Hou C., Wu W., Wang X., et al. (2021). Analysis of MT-ND gene variation in two children with Leigh disease who presented long segment spinal cord magnetic resonance imaging abnormalities. Chin J. Pediatr 59 (02), 136–138. 10.3760/cma.j.cn112140-20200919-00890 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Table1.docx (73.4KB, docx)

Data Availability Statement

The datasets presented in this article are not readily available because of ethical and privacy restrictions. Requests to access the de-identified final clinical sequencing report supporting the conclusions of this article should be directed to the corresponding author/s, subject to institutional ethical approval.


Articles from Frontiers in Genetics are provided here courtesy of Frontiers Media SA

RESOURCES